The following is a quick brief of what MDRM has been up to lately.
Email exchange between myself and MDRM IR.
Original Message
From: **************
Sent: September-09-14 5:48 PM
To: investor@mdrmgroup.com
Subject: MDRM investment
Hello,
I am a member of an investment team excited about MDRM's future in the
biopharma industry. Although I'm quite aware of the sluggishness of Health
Canada and the over abundance of applications pouring in to them I still
need to ask if MDRM has any plans to fix the current situation with the
price per share. Although i realize that having a PPS in the high teens
most likely came across as phoney and almost embarrassing so soon after
moving into the MMJ market, the current PPS is extremely low and volume is
nearly non existent. We, as investors need news. We are seeing shares
being sold far below market value which is worrying investors greatly. I
would be extremely grateful for some info so that I may pass it on. One
good thing about this price is that it is a great entry price. But we need
confirmation that MDRM is on the right track.
What I would like to know, is the MDRM team working on anything to get this
share price moving or is MDRM content with keeping the price low until the
licences from Health Canada come in. I do have confidence in the
acquisition of licence(s) in the future. But is the strategy to simply wait
out for these licenses or is there an immediate game plan until then?
Does MDRM have a plan to acquire a closed loop payment card to combat the
money and payment issues from customers for their medication?
Does MDRM have any plans to be involved in business outside of MMJ or do
they plan on entering any other markets?
Will MDRM be changing their name or keeping as is?
Is MDRM interested in a merger or RTO with a private company in which
funding would be more easily available?
When can we expect the next asset or acquisition to be PR'd?
Is MDRM avoiding updating its investors to stay away from the "Pump and
Dump" MMJ stigma that seems to be haunting all new companies in this market?
Further this last question, now that MDRM is current, why havent you been
more clear with the deals that have been pulled out of the Q reports? Have
they fallen through?
Are you still doing business with EAPH and is this dispensary the one they
are reporting about that has failed their final inspection due to a lighting
issue. Is this your dispensary?
How many dispensaries do you currently have ownership in? whether it be 100%
or partial ownership in?
When can we expect a legitimate MDRM PR update?
Thanks in advance for all your help and I will pass this information on to
my team and other investors inquiring and interested in investing in MDRM.
Regards,
Brent
——————————————————————————————————————
Original message
From: MDRM Investor Relations <investor@mdrmgroup.com>
Date:09-14-2014 11:38 AM (GMT-05:00)
To: ‘*’***************** <*******************>
Cc:
Subject: RE: MDRM investment
Dear Mr. ***************
Thank you for your confidence and support of MDRM
In order to avoid any suggestion of "pump and dump" or taking advantage of
"marijuana hype" MDRM has refrained from making any public announcements and has
been actively engaged in building a solid business path. Any deals stated in
the filings are still being pursued and MDRM will be completing the purchase
of a licensed medical marijuana facility in the very near future. MDRM
has also acquired a licensing agreement to manufacture and market a medical
device.
MDRM has assembled a top notch medical and business team and intends to
make several public disclosures in the next 60 days, including a name
change. I am afraid this is all we can disclose at the moment but watch for
exciting public announcements in the next few weeks.
Thanks you
John Daldin
———————————————————————————————————————
From: *********************** Sent: September-14-14 12:11 PM To: MDRM Investor Relations Subject: RE: MDRM investment
Thank you so much for your informative reply sir.
May I share this email publicly or would you prefer it to be kept private? Thanks again for your speedy reply.
Also could you supply me with your position within the company if possibly.
Regards,
*******************
———————————————————————————————————————
Original message From: MDRM Investor Relations <investor@mdrmgroup.com> Date:09-15-2014 8:33 AM (GMT-05:00) To: *********************** Cc: Subject: RE: MDRM investment
This information provided to you is not for public release yet
I have retained recently by MDRM to handle the investor relations
Thanks
John
EMAIL EXCHANGE ENDS
———————————————————————————————————————
2014 info Pulled from Quarterlies and PR's:
Memorandums of Understanding
On March 28, 2014, through a wholly-owned subsidiary incorporated under the laws of Ontario, Canada, we entered into a Memorandum of Understanding to purchase 67% of a private company with a pending application for a license from Health Canada under the recently enacted Marijuana for Medical Purposes Regulation (“MMPR”). The facilities are located in the Province of Ontario. In addition, the agreement provides that we will also acquire a 50% interest in a related private corporation which has received a “ready to build” letter from Health Canada in conjunction with a pending application for a license to conduct research on marijuana. The closing of this transaction is contingent on the issuance of the respective licenses by Health Canada.
On June 27, 2014 the Company entered into an agreement with DYMA INC., a company incorporated in the Province of Ontario that previously operated a 6000 sq. ft facility under MMAR and is pending a license from Health Canada under MMPR. The Company purchased 308,000 shares of DYMA INC common stock at $0.75 per share representing approximately 14% of the DYMA INC's stock when a current offering is fully subscribed. The highly experienced owners and management of DYMA INC. are actively assisting the MDMR in further assessing and building-out other targeted acquisitions.
On May 8, 2014, through a wholly-owned subsidiary formed in Ontario, Canada, we entered into an agreement to purchase 100% of a private company in the final stage of obtaining their Medical Marijuana growers license. The company, located in the Province of Ontario, owns a fully functional production facility, and is awaiting final inspection by Health Canada, the federal department responsible for administering the healthcare system in Canada. The transaction includes real property and related facilities. Under the terms of the agreement, the Company will pay CDN$2.5 million at Closing with an additional CDN$2.5 million due at a deferred date. The Company will also issue a warrant to the sellers to purchase up to 1 million shares of the Company shares at a 25% discount to market. The closing of the purchase is subject to receipt of a license from Health Canada under MMPR.
The Company is actively and aggressively pursuing various other opportunities within the medical marijuana sector. To this end, we have entered into letters of intent to purchase controlling interests in two other private companies each in the final stages of obtaining their Medical Marijuana growers license. The actual terms and conditions of these two proposed transactions will be disclosed at such time as the Company has entered into definitive agreements on the matters.
The Company, through a wholly-owned subsidiary, MDRM Group (Canada) Ltd., formed in Ontario, Canada, entered into an acquisition agreement on May 8, 2014 with a private Ontario company (“Potential Licensee”) to acquire 100% of the issued and outstanding shares of Potential Licensee. The Potential Licensee is in the final stage of obtaining their Medical Marijuana growers license. The Potential Licensee is located in the Province of Ontario, owns a fully functional production facility, and is awaiting final inspection by Health Canada. The transaction includes real property and related facilities. Pursuant to the terms of the acquisition agreement, the Company paid a non-refundable advance against acquisition of $46,000 to the law firm of the sellers, in Trust, in the transaction. On the instruction of the Company, on June 18, 2014, an amount of $41,400 was released to the vendor from the Trust account leaving a balance of $4,400 in the trust account.
Under the terms of the acquisition agreement, the Company will pay CDN$2.5 million at Closing with an additional CDN$2.5 million due on the first anniversary date of the Closing. The Company will also issue, at Closing, a warrant to the sellers to purchase up to 1 million shares of the Company shares at a 25% discount to market. The Closing of the acquisition agreement is subject to receipt of a license from Health Canada under Marijuana for Medical Purposes Regulation ("MMPR"
.
On May 27, 2014, the Company, through its wholly-owned subsidiary, MDRM Group (Canada) Ltd, entered into an agreement with a Wyoming registered public company (the "Public Company" , to sell up to forty-nine percent (49%) of the shares of the Potential Licensee, for a total purchase consideration of $2,486,946. At the execution and acceptance of the said agreement, the Private Company paid a non-refundable sum of $23,070 to the Company for the option right granted under the said agreement to acquire shares of the Potential Licensee.
The Company is actively and aggressively pursuing various other opportunities relating to the medical marijuana and biopharma industries which meet its investment criteria. To this end, we have entered into letters of intent to purchase controlling interests in two other private companies each in the final stages of obtaining their Medical Marijuana growers license. The actual terms and conditions of these two proposed transactions will be disclosed at such time as the Company has entered into definitive agreements on the matters.
"The primary Potential Licensee that the Company has under contract to purchase is Health Canada application No. 7. The Potential Licensee has a “ready-to-build” letter from Health Canada with provision for inspection notice for its production license. The required improvements have been substantially completed and the Company expects that the Potential Licensee will be able to call for an inspection by Health Canada within the fourth calendar quarter of 2014."
The Medical Advisory Board (Advisory Board) comprises primarily of doctors in various fields of medicine in which cannabis has been used either experimentally or in a medical prescription capacity. While each member of this board has established themselves as a leader within their respective fields, it was imperative to have representation from the full expanse of medical fields in which medical cannabis has indications.
The Advisory Board will serve to inform and advise management in biomedical research and the medical prescriptive use of cannabis in the bests interests of patient welfare. The Advisory Board will make recommendations to management that promotes education and awareness within the company and the medical community at large regarding the known effects of the use of cannabis. The Advisory Board will also do research on scientific programs of interest to management.
The Advisory Board may consist of up to 10 members whose terms may be up to 4 years and renewable. Appointments are made by the President of the company in consultation with the CMD. The CEO and President of the company are ex officio members of the Advisory Board.
Members of the Advisory Board are:
Baseer U. Khan, MD, FRCS(C)
Dr. Khan uniquely brings both medical and business expertise to MDRM. Clinically, Dr. Khan is an internationally recognized surgeon, researcher, and consultant. He is an Assistant Professor, University of Toronto and Executive Lead Physician, Eye Institute, Southlake Regional Hospital, Newmarket Ontario. Corporately, Dr. Khan founded and established the largest private ophthalmic practice in Toronto (Clarity Eye Institute), and is a managing partner and CIO of Oneview Procurement Solutions.
Gilbert Sharpe, Esq.
Gilbert Sharpe is a partner in the Health Law Group at the Toronto based law firm of Fasken Martineau. Mr. Sharpe, the former long-time Director of the Legal Branch of the Ontario Ministry of Health and Long-Term Care, brings invaluable experience from a distinguished 30-year career in legal practice and advisory roles. His background in public policy, private sector involvement and college regulatory work is a great asset to MDRM. Through his involvement with the Ministry of Health since 1975, and associated work with numerous ministries and agencies of the Ontario government as well as federal departments, Mr. Sharpe has been involved continuously with important legal issues and policy matters affecting health care, including the development of legislation and policies to improve the health care system. As well, he has been an advocate for educational forums to promote ongoing and effective exchange of information related to new initiatives. Since leaving the Ontario government, Mr. Sharpe has continued to work on numerous health law and policy matters for various clients, both in the private and public sectors. Mr. Sharpe holds several professorships (Professor, Faculty of Health Sciences, McMaster University; Professor, Faculty of Medicine, University of Toronto) as well as other positions including President of the Canadian Institute of Law and Medicine and Editor-in-Chief of Health Law in Canada. He is a member of the Canadian Bar Association and the Ontario Bar Association.
Dr. Peter J. Rothbart, MD, FRCP, DABPM:
Founder of the Rothbart Center for Pain Care and the Past President of the Chronic Pain Section of the Ontario Medical Association, Dr. Rothbart is recognized internationally as a leader and pioneer in the area of Chronic Pain Management.
Dr. Keith Jarvi, MD, FRCS
Dr. Jarvi is the Director of the Murray Koffler Urologic Wellness Centre and Head of Urology at the Mount Sinai Hospital. He is a Professor of Surgery at the University of Toronto and directs the Male Infertility Program at the University of Toronto. Dr. Jarvi has pioneered several echniques in urological surgery, published extensively on his research interests, and is internationally recognized in his field.
Dr. J. Brendan M. Mullen, MD, FRCP
Dr. Mullen is currently Director of the Andrology Laboratory and Deputy Director of Laboratories in the Department of Pathology and Laboratory Medicine at Mount Sinai Hospital and Laboratory Director for Flow Health Services Incorporated. He is an Associate Professor of Laboratory Medicine and Pathobiology, Anesthesia and Urology at the University of Toronto. He chaired and been consulted on a many provincial initiatives focused on identification and implementation of best practice policies. Dr. Mullen is heavily involved in research and has published extensively.
Dr. Paul Sanghera, MD, FRCS
Dr. Sanghera is on staff at Mount Sinai Hospital, in the department of Ophthalmology, and the Kensington Eye Institute, both located in Toronto, Ontario. He also serves as the co-chairman of the International Ophthalmology Program at the University of Toronto. A innovator and teacher, Dr. Sanghera was one of the first surgeons in Canada to perform laser cataract surgery, and in 2014, he co-created and co-chaired Canada's first laser cataract teaching symposium.
Dr. Duncan A. Scott, MD, FRCPC
Dr. Scott's principle focus is on forensic psychiatry however Dr. Scott has a wide ranging field of expertise and acts as an expert witness for both the Crown and defense attorneys. Among his many professional affiliations, he is a member of the Canadian Society of Medical Examiners, Canadian Academy of Psychiatry and Law and a past President of the Association of Physicians in Corrections of Ontario.
Dr. Adam Blackman, MD, D.ABSM, D.ABPN, FRCPC
Dr. Blackman is a board certified psychiatrist who sub-specialized in Sleep Medicine. He is the founder and Chief Medical Director of Medsleep, the past hair of the Section on Sleep Disorders of the Ontario Medical Association and an Assessor for the College of Physicians and Surgeons of Ontario. He has been a member of multiple committees responsible for the Clinical and Best Practice Guidelines. As an assistant professor at the University of Toronto, Dr. Blackman is actively involved in teaching and research.
MDRM believes that with the appointment of this highly qualified Advisory Board, it is establishing itself as a leader and innovator in the development of the Medical Cannabis industry in Canada.
About Modern Mobility Aids, Inc.
Modern Mobility Aids, Inc. is a public company in the biotechnology, life sciences and healthcare industry focused, in part, on the production, cultivation and selling of Medical Marijuana in North America. Our objective is to provide patients with access to a standardized and trusted supply of pharmaceutical grade cannabis developed and processed in accordance with rigorous health and safety standards and produced under Good Manufacturing Practices, the criteria used to manufacture all pharmaceuticals in the United States and Canada, ensuring a safe and reliable product. The Company is positioned to acquire interests in companies within the medical devices, biopharma and alternative medicine sectors targeting both innovative research and development as well as scalable licensed, manufacturing capacity in the three targeted niche market segments.
Email exchange between myself and MDRM IR.
Original Message
From: **************
Sent: September-09-14 5:48 PM
To: investor@mdrmgroup.com
Subject: MDRM investment
Hello,
I am a member of an investment team excited about MDRM's future in the
biopharma industry. Although I'm quite aware of the sluggishness of Health
Canada and the over abundance of applications pouring in to them I still
need to ask if MDRM has any plans to fix the current situation with the
price per share. Although i realize that having a PPS in the high teens
most likely came across as phoney and almost embarrassing so soon after
moving into the MMJ market, the current PPS is extremely low and volume is
nearly non existent. We, as investors need news. We are seeing shares
being sold far below market value which is worrying investors greatly. I
would be extremely grateful for some info so that I may pass it on. One
good thing about this price is that it is a great entry price. But we need
confirmation that MDRM is on the right track.
What I would like to know, is the MDRM team working on anything to get this
share price moving or is MDRM content with keeping the price low until the
licences from Health Canada come in. I do have confidence in the
acquisition of licence(s) in the future. But is the strategy to simply wait
out for these licenses or is there an immediate game plan until then?
Does MDRM have a plan to acquire a closed loop payment card to combat the
money and payment issues from customers for their medication?
Does MDRM have any plans to be involved in business outside of MMJ or do
they plan on entering any other markets?
Will MDRM be changing their name or keeping as is?
Is MDRM interested in a merger or RTO with a private company in which
funding would be more easily available?
When can we expect the next asset or acquisition to be PR'd?
Is MDRM avoiding updating its investors to stay away from the "Pump and
Dump" MMJ stigma that seems to be haunting all new companies in this market?
Further this last question, now that MDRM is current, why havent you been
more clear with the deals that have been pulled out of the Q reports? Have
they fallen through?
Are you still doing business with EAPH and is this dispensary the one they
are reporting about that has failed their final inspection due to a lighting
issue. Is this your dispensary?
How many dispensaries do you currently have ownership in? whether it be 100%
or partial ownership in?
When can we expect a legitimate MDRM PR update?
Thanks in advance for all your help and I will pass this information on to
my team and other investors inquiring and interested in investing in MDRM.
Regards,
Brent
——————————————————————————————————————
Original message
From: MDRM Investor Relations <investor@mdrmgroup.com>
Date:09-14-2014 11:38 AM (GMT-05:00)
To: ‘*’***************** <*******************>
Cc:
Subject: RE: MDRM investment
Dear Mr. ***************
Thank you for your confidence and support of MDRM
In order to avoid any suggestion of "pump and dump" or taking advantage of
"marijuana hype" MDRM has refrained from making any public announcements and has
been actively engaged in building a solid business path. Any deals stated in
the filings are still being pursued and MDRM will be completing the purchase
of a licensed medical marijuana facility in the very near future. MDRM
has also acquired a licensing agreement to manufacture and market a medical
device.
MDRM has assembled a top notch medical and business team and intends to
make several public disclosures in the next 60 days, including a name
change. I am afraid this is all we can disclose at the moment but watch for
exciting public announcements in the next few weeks.
Thanks you
John Daldin
———————————————————————————————————————
From: *********************** Sent: September-14-14 12:11 PM To: MDRM Investor Relations Subject: RE: MDRM investment
Thank you so much for your informative reply sir.
May I share this email publicly or would you prefer it to be kept private? Thanks again for your speedy reply.
Also could you supply me with your position within the company if possibly.
Regards,
*******************
———————————————————————————————————————
Original message From: MDRM Investor Relations <investor@mdrmgroup.com> Date:09-15-2014 8:33 AM (GMT-05:00) To: *********************** Cc: Subject: RE: MDRM investment
This information provided to you is not for public release yet
I have retained recently by MDRM to handle the investor relations
Thanks
John
EMAIL EXCHANGE ENDS
———————————————————————————————————————
2014 info Pulled from Quarterlies and PR's:
Memorandums of Understanding
On March 28, 2014, through a wholly-owned subsidiary incorporated under the laws of Ontario, Canada, we entered into a Memorandum of Understanding to purchase 67% of a private company with a pending application for a license from Health Canada under the recently enacted Marijuana for Medical Purposes Regulation (“MMPR”). The facilities are located in the Province of Ontario. In addition, the agreement provides that we will also acquire a 50% interest in a related private corporation which has received a “ready to build” letter from Health Canada in conjunction with a pending application for a license to conduct research on marijuana. The closing of this transaction is contingent on the issuance of the respective licenses by Health Canada.
On June 27, 2014 the Company entered into an agreement with DYMA INC., a company incorporated in the Province of Ontario that previously operated a 6000 sq. ft facility under MMAR and is pending a license from Health Canada under MMPR. The Company purchased 308,000 shares of DYMA INC common stock at $0.75 per share representing approximately 14% of the DYMA INC's stock when a current offering is fully subscribed. The highly experienced owners and management of DYMA INC. are actively assisting the MDMR in further assessing and building-out other targeted acquisitions.
On May 8, 2014, through a wholly-owned subsidiary formed in Ontario, Canada, we entered into an agreement to purchase 100% of a private company in the final stage of obtaining their Medical Marijuana growers license. The company, located in the Province of Ontario, owns a fully functional production facility, and is awaiting final inspection by Health Canada, the federal department responsible for administering the healthcare system in Canada. The transaction includes real property and related facilities. Under the terms of the agreement, the Company will pay CDN$2.5 million at Closing with an additional CDN$2.5 million due at a deferred date. The Company will also issue a warrant to the sellers to purchase up to 1 million shares of the Company shares at a 25% discount to market. The closing of the purchase is subject to receipt of a license from Health Canada under MMPR.
The Company is actively and aggressively pursuing various other opportunities within the medical marijuana sector. To this end, we have entered into letters of intent to purchase controlling interests in two other private companies each in the final stages of obtaining their Medical Marijuana growers license. The actual terms and conditions of these two proposed transactions will be disclosed at such time as the Company has entered into definitive agreements on the matters.
The Company, through a wholly-owned subsidiary, MDRM Group (Canada) Ltd., formed in Ontario, Canada, entered into an acquisition agreement on May 8, 2014 with a private Ontario company (“Potential Licensee”) to acquire 100% of the issued and outstanding shares of Potential Licensee. The Potential Licensee is in the final stage of obtaining their Medical Marijuana growers license. The Potential Licensee is located in the Province of Ontario, owns a fully functional production facility, and is awaiting final inspection by Health Canada. The transaction includes real property and related facilities. Pursuant to the terms of the acquisition agreement, the Company paid a non-refundable advance against acquisition of $46,000 to the law firm of the sellers, in Trust, in the transaction. On the instruction of the Company, on June 18, 2014, an amount of $41,400 was released to the vendor from the Trust account leaving a balance of $4,400 in the trust account.
Under the terms of the acquisition agreement, the Company will pay CDN$2.5 million at Closing with an additional CDN$2.5 million due on the first anniversary date of the Closing. The Company will also issue, at Closing, a warrant to the sellers to purchase up to 1 million shares of the Company shares at a 25% discount to market. The Closing of the acquisition agreement is subject to receipt of a license from Health Canada under Marijuana for Medical Purposes Regulation ("MMPR"
. On May 27, 2014, the Company, through its wholly-owned subsidiary, MDRM Group (Canada) Ltd, entered into an agreement with a Wyoming registered public company (the "Public Company"
, to sell up to forty-nine percent (49%) of the shares of the Potential Licensee, for a total purchase consideration of $2,486,946. At the execution and acceptance of the said agreement, the Private Company paid a non-refundable sum of $23,070 to the Company for the option right granted under the said agreement to acquire shares of the Potential Licensee. The Company is actively and aggressively pursuing various other opportunities relating to the medical marijuana and biopharma industries which meet its investment criteria. To this end, we have entered into letters of intent to purchase controlling interests in two other private companies each in the final stages of obtaining their Medical Marijuana growers license. The actual terms and conditions of these two proposed transactions will be disclosed at such time as the Company has entered into definitive agreements on the matters.
"The primary Potential Licensee that the Company has under contract to purchase is Health Canada application No. 7. The Potential Licensee has a “ready-to-build” letter from Health Canada with provision for inspection notice for its production license. The required improvements have been substantially completed and the Company expects that the Potential Licensee will be able to call for an inspection by Health Canada within the fourth calendar quarter of 2014."
The Medical Advisory Board (Advisory Board) comprises primarily of doctors in various fields of medicine in which cannabis has been used either experimentally or in a medical prescription capacity. While each member of this board has established themselves as a leader within their respective fields, it was imperative to have representation from the full expanse of medical fields in which medical cannabis has indications.
The Advisory Board will serve to inform and advise management in biomedical research and the medical prescriptive use of cannabis in the bests interests of patient welfare. The Advisory Board will make recommendations to management that promotes education and awareness within the company and the medical community at large regarding the known effects of the use of cannabis. The Advisory Board will also do research on scientific programs of interest to management.
The Advisory Board may consist of up to 10 members whose terms may be up to 4 years and renewable. Appointments are made by the President of the company in consultation with the CMD. The CEO and President of the company are ex officio members of the Advisory Board.
Members of the Advisory Board are:
Baseer U. Khan, MD, FRCS(C)
Dr. Khan uniquely brings both medical and business expertise to MDRM. Clinically, Dr. Khan is an internationally recognized surgeon, researcher, and consultant. He is an Assistant Professor, University of Toronto and Executive Lead Physician, Eye Institute, Southlake Regional Hospital, Newmarket Ontario. Corporately, Dr. Khan founded and established the largest private ophthalmic practice in Toronto (Clarity Eye Institute), and is a managing partner and CIO of Oneview Procurement Solutions.
Gilbert Sharpe, Esq.
Gilbert Sharpe is a partner in the Health Law Group at the Toronto based law firm of Fasken Martineau. Mr. Sharpe, the former long-time Director of the Legal Branch of the Ontario Ministry of Health and Long-Term Care, brings invaluable experience from a distinguished 30-year career in legal practice and advisory roles. His background in public policy, private sector involvement and college regulatory work is a great asset to MDRM. Through his involvement with the Ministry of Health since 1975, and associated work with numerous ministries and agencies of the Ontario government as well as federal departments, Mr. Sharpe has been involved continuously with important legal issues and policy matters affecting health care, including the development of legislation and policies to improve the health care system. As well, he has been an advocate for educational forums to promote ongoing and effective exchange of information related to new initiatives. Since leaving the Ontario government, Mr. Sharpe has continued to work on numerous health law and policy matters for various clients, both in the private and public sectors. Mr. Sharpe holds several professorships (Professor, Faculty of Health Sciences, McMaster University; Professor, Faculty of Medicine, University of Toronto) as well as other positions including President of the Canadian Institute of Law and Medicine and Editor-in-Chief of Health Law in Canada. He is a member of the Canadian Bar Association and the Ontario Bar Association.
Dr. Peter J. Rothbart, MD, FRCP, DABPM:
Founder of the Rothbart Center for Pain Care and the Past President of the Chronic Pain Section of the Ontario Medical Association, Dr. Rothbart is recognized internationally as a leader and pioneer in the area of Chronic Pain Management.
Dr. Keith Jarvi, MD, FRCS
Dr. Jarvi is the Director of the Murray Koffler Urologic Wellness Centre and Head of Urology at the Mount Sinai Hospital. He is a Professor of Surgery at the University of Toronto and directs the Male Infertility Program at the University of Toronto. Dr. Jarvi has pioneered several echniques in urological surgery, published extensively on his research interests, and is internationally recognized in his field.
Dr. J. Brendan M. Mullen, MD, FRCP
Dr. Mullen is currently Director of the Andrology Laboratory and Deputy Director of Laboratories in the Department of Pathology and Laboratory Medicine at Mount Sinai Hospital and Laboratory Director for Flow Health Services Incorporated. He is an Associate Professor of Laboratory Medicine and Pathobiology, Anesthesia and Urology at the University of Toronto. He chaired and been consulted on a many provincial initiatives focused on identification and implementation of best practice policies. Dr. Mullen is heavily involved in research and has published extensively.
Dr. Paul Sanghera, MD, FRCS
Dr. Sanghera is on staff at Mount Sinai Hospital, in the department of Ophthalmology, and the Kensington Eye Institute, both located in Toronto, Ontario. He also serves as the co-chairman of the International Ophthalmology Program at the University of Toronto. A innovator and teacher, Dr. Sanghera was one of the first surgeons in Canada to perform laser cataract surgery, and in 2014, he co-created and co-chaired Canada's first laser cataract teaching symposium.
Dr. Duncan A. Scott, MD, FRCPC
Dr. Scott's principle focus is on forensic psychiatry however Dr. Scott has a wide ranging field of expertise and acts as an expert witness for both the Crown and defense attorneys. Among his many professional affiliations, he is a member of the Canadian Society of Medical Examiners, Canadian Academy of Psychiatry and Law and a past President of the Association of Physicians in Corrections of Ontario.
Dr. Adam Blackman, MD, D.ABSM, D.ABPN, FRCPC
Dr. Blackman is a board certified psychiatrist who sub-specialized in Sleep Medicine. He is the founder and Chief Medical Director of Medsleep, the past hair of the Section on Sleep Disorders of the Ontario Medical Association and an Assessor for the College of Physicians and Surgeons of Ontario. He has been a member of multiple committees responsible for the Clinical and Best Practice Guidelines. As an assistant professor at the University of Toronto, Dr. Blackman is actively involved in teaching and research.
MDRM believes that with the appointment of this highly qualified Advisory Board, it is establishing itself as a leader and innovator in the development of the Medical Cannabis industry in Canada.
About Modern Mobility Aids, Inc.
Modern Mobility Aids, Inc. is a public company in the biotechnology, life sciences and healthcare industry focused, in part, on the production, cultivation and selling of Medical Marijuana in North America. Our objective is to provide patients with access to a standardized and trusted supply of pharmaceutical grade cannabis developed and processed in accordance with rigorous health and safety standards and produced under Good Manufacturing Practices, the criteria used to manufacture all pharmaceuticals in the United States and Canada, ensuring a safe and reliable product. The Company is positioned to acquire interests in companies within the medical devices, biopharma and alternative medicine sectors targeting both innovative research and development as well as scalable licensed, manufacturing capacity in the three targeted niche market segments.
